{
    "clinical_study": {
        "@rank": "88944", 
        "acronym": "DAILY", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This prospective, non-interventional, multi-center study documents observational data on\n      subjects under routine treatment of Pulmonary Arterial Hypertension, functional class III\n      with inhaled Iloprost administered with I-Neb AAD (Adaptive Aerosol Delivery) device. The\n      observation period for each subject covers a one year treatment period with inhaled\n      Ventavis. For each subject, the investigator or a delegate collects data as defined in the\n      case report form at an initial visit, routine follow-up visit at 6 months and final visit at\n      12 months."
        }, 
        "brief_title": "Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects aged \u226518 years\n\n          -  Newly Treated with Ventavis or treated with Ventavis for less than 6 months, with I\n             Neb AAD device for the application, as described in the SmPC (Summary of Product\n             Characteristics), complemented by the Insight\n\n          -  With Pulmonary Arterial Hypertension, Group I of the Dana point Pulmonary\n             Hypertension Classification.\n\n          -  WHO (World Health Organization) /NYHA (New York Heart Association) Functional class\n             III\n\n          -  Able and willing to give written informed consent for participation in the study\n\n        Exclusion Criteria:\n\n        Key contra indications:\n\n          -  Hypersensitivity to the active substance or to any of the excipients.\n\n          -  Conditions where the effects of Ventavis on platelets might increase the risk of\n             haemorrhage (e.g. active peptic ulcers, trauma, intracranial haemorrhage).\n\n          -  Severe coronary heart disease or unstable angina;\n\n          -  Myocardial infarction within the last six months;\n\n          -  Decompensated cardiac failure if not under close medical supervision;\n\n          -  Severe arrhythmias;\n\n          -  Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3\n             months.\n\n          -  Pulmonary hypertension due to venous occlusive disease.\n\n          -  Congenital or acquired valvular defects with clinically relevant myocardial function\n             disorders not related to pulmonary hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients aged \u226518 years and diagnosed with PAH (Pulmonary Arterial Hypertension), WHO/NYHA\n        functional class III, Group I of the Dana point Pulmonary Hypertension Classification and\n        newly Treated with Ventavis or treated with Ventavis for less than 6 months, with I-Neb\n        AAD device for the application."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781052", 
            "org_study_id": "16133", 
            "secondary_id": [
                "VE1210FR", 
                "2011/00416"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Initial dose: 2.5 \u00b5g per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 \u00b5g per inhalation session.", 
            "intervention_name": "Ventavis (Iloprost, BAYQ6256)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Iloprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Iloprost Compliance", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "France"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "DAILY: Observational Description of Compliance for the Daily Ventavis\u00ae Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: none", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compliance of Ventavis use for each subject assessed by the mean daily number of inhalations and mean daily dose of Ventavis.", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compliance of Ventavis use for each subject assessed by the mean daily number of inhalations and mean daily dose of Ventavis", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Total distance (meters) walked within 6 minutes assessed by the 6 Minutes Walking Distance Test", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Dyspnea Borg Category Ration 10 Scale values", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Quality of Life (EQ5D and LPH [Living with Pulmonary Hypertension] questionnaires)", 
                "safety_issue": "No", 
                "time_frame": "6 and 12 months"
            }, 
            {
                "measure": "Investigator and patient satisfaction in the use of I-neb Insight tool assessed by a five level likert scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}